Burdis, Nora
Kapnadak, Siddhartha G.
Bartlett, Lauren E.
McElvaney, Oliver
Milinic, Tijana
Wai, Travis Hee
Lange, Allison V.
Reid, Nick
Dunitz, Jordan M.
Billings, Joanne L.
Pilewski, Joseph M.
Saavedra, Milene
Goss, Christopher H.
Hartzler, Andrea L.
Ramos, Kathleen J.
Funding for this research was provided by:
National Institutes of Health (T32 HL125195, P30 DK089507, K23HL138154)
Cystic Fibrosis Foundation (RAMOS17A0)
Article History
Received: 22 February 2024
Accepted: 11 July 2024
First Online: 18 July 2024
Declarations
:
: UW IRB approval was obtained (Study #7475) for survey distribution and the collection of clinical information. An IRB-approved phone script was used to recruit individuals.
: Not applicable.
: KJR: Vertex Pharmaceuticals honoraria and travel support. CHG: Enterprise Therapeutics consulting fees & travel costs, Vertex Pharmaceuticals honoraria & travel costs, Gilead Sciences honoraria, Deputy Editor of Annals of ATS, DSMB Chair for Novartis trial. Other authors’ declarations of interest: none.